BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 24260500)

  • 1. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of Gastric Cancer by Successive Oncogenic Activation in the Corpus.
    Douchi D; Yamamura A; Matsuo J; Melissa Lim YH; Nuttonmanit N; Shimura M; Suda K; Chen S; Pang S; Kohu K; Abe T; Shioi G; Kim G; Shabbir A; Srivastava S; Unno M; Bok-Yan So J; Teh M; Yeoh KG; Chuang LSH; Ito Y
    Gastroenterology; 2021 Dec; 161(6):1907-1923.e26. PubMed ID: 34391772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
    Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
    Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ETS1 regulates Twist1 transcription in a Kras
    Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
    Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
    Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
    Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
    Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
    Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
    Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK
    J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
    Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
    J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
    Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
    Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.
    Baumgart A; Mazur PK; Anton M; Rudelius M; Schwamborn K; Feuchtinger A; Behnke K; Walch A; Braren R; Peschel C; Duyster J; Siveke JT; Dechow T
    Oncogene; 2015 Jan; 34(5):578-88. PubMed ID: 24509876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the Kras
    Weng CC; Hawse JR; Subramaniam M; Chang VHS; Yu WCY; Hung WC; Chen LT; Cheng KH
    Oncogene; 2017 Sep; 36(39):5532-5543. PubMed ID: 28581520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
    Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; GutiƩrrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
    Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
    [No Abstract]   [Full Text] [Related]  

  • 16. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
    Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
    Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.
    Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X
    Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
    Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
    Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
    Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
    Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.